open access

Vol 21, No 1 (2018)
Original articles
Published online: 2018-01-05
Submitted: 2017-07-13
Accepted: 2018-01-02
Get Citation

A study on drug delivery tracing with radiolabeled mesoporous hydroxyapatite nanoparticles conjugated with 2DG/DOX for breast tumor cells

Mahdiyeh Shamsi, Jafar Majidi Zolbanin, Babak Mahmoudian, Naime Majidi Zolbanin, Leili Aghebati Maleki, Mohammad Asghari Jafarabadi, Jalil Pirayesh Islamian
DOI: 10.5603/NMR.a2018.0008
·
Pubmed: 29319137
·
Nucl. Med. Rev 2018;21(1):32-36.

open access

Vol 21, No 1 (2018)
Original articles
Published online: 2018-01-05
Submitted: 2017-07-13
Accepted: 2018-01-02

Abstract

Background: Mesoporous nanoparticles have a great potential in targeted therapy approaches due to their ideal properties for encapsulation of various drugs, proteins and also biologically active molecules. Material and methods: We used mesoporous hydroxyapatite (HA) nanoparticles as a drug carrier and developed radiolabeled mesoporous HA containing of 2-deoxy-D-glucose (2DG) and Doxorubicin (DOX) with technetium-99m (99mTc) for imaging in in vitro and in vivo studies. Results: 2DG and DOX in presence of mesoporous HA nanoparticles more reduced the fraction of viable cells in the MDA-MB-231, MCF-7 human and MC4-L2 Balb/c mice breast cancer cells. The radiochemical purity of the nano-2DG-DOX complex with 99mTc was calculated to 96.8%. The results of cellular uptake showed a 44.77% increase in uptake of the [99mTc]-nano-2DG-DOX compared to the complex without nanoparticles (p < 0.001). Conclusion: Radioisotopic imaging demonstrated a high biochemical stability for [99mTc]-nano-2DG-DOX complex. The results demonstrated that [99mTc]-nano-2DG-DOX, may be used as an attractive candidate in cancer imaging and treatment managing.

Abstract

Background: Mesoporous nanoparticles have a great potential in targeted therapy approaches due to their ideal properties for encapsulation of various drugs, proteins and also biologically active molecules. Material and methods: We used mesoporous hydroxyapatite (HA) nanoparticles as a drug carrier and developed radiolabeled mesoporous HA containing of 2-deoxy-D-glucose (2DG) and Doxorubicin (DOX) with technetium-99m (99mTc) for imaging in in vitro and in vivo studies. Results: 2DG and DOX in presence of mesoporous HA nanoparticles more reduced the fraction of viable cells in the MDA-MB-231, MCF-7 human and MC4-L2 Balb/c mice breast cancer cells. The radiochemical purity of the nano-2DG-DOX complex with 99mTc was calculated to 96.8%. The results of cellular uptake showed a 44.77% increase in uptake of the [99mTc]-nano-2DG-DOX compared to the complex without nanoparticles (p < 0.001). Conclusion: Radioisotopic imaging demonstrated a high biochemical stability for [99mTc]-nano-2DG-DOX complex. The results demonstrated that [99mTc]-nano-2DG-DOX, may be used as an attractive candidate in cancer imaging and treatment managing.
Get Citation

Keywords

2-deoxy-D-glucose, breast cancer, doxorubicin, nanoparticle, targeted therapy, 99mTc

About this article
Title

A study on drug delivery tracing with radiolabeled mesoporous hydroxyapatite nanoparticles conjugated with 2DG/DOX for breast tumor cells

Journal

Nuclear Medicine Review

Issue

Vol 21, No 1 (2018)

Pages

32-36

Published online

2018-01-05

DOI

10.5603/NMR.a2018.0008

Pubmed

29319137

Bibliographic record

Nucl. Med. Rev 2018;21(1):32-36.

Keywords

2-deoxy-D-glucose
breast cancer
doxorubicin
nanoparticle
targeted therapy
99mTc

Authors

Mahdiyeh Shamsi
Jafar Majidi Zolbanin
Babak Mahmoudian
Naime Majidi Zolbanin
Leili Aghebati Maleki
Mohammad Asghari Jafarabadi
Jalil Pirayesh Islamian

References (29)
  1. Chen F, Hong H, Zhang Y, et al. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano. 2013; 7(10): 9027–9039.
  2. Aval NA, Islamian JP, Hatamian M, et al. Doxorubicin loaded large-pore mesoporous hydroxyapatite coated superparamagnetic Fe 3 O 4 nanoparticles for cancer treatment. International Journal of Pharmaceutics. 2016; 509(1-2): 159–167.
  3. Aval NA, Javadpour J, Badiei A. Application of sucrose as a cosurfactant in controlling the pore diameter in the synthesis of mesoporous hydroxyapatite nanoparticles. Ceramics–Silikáty. 2015; 59(4): 311–317.
  4. Psimadas D, Bouziotis P, Georgoulias P, et al. Radiolabeling approaches of nanoparticles with (99m) Tc. Contrast Media Mol Imaging. 2013; 8(4): 333–339.
  5. Albernaz Md, Ospina CA, Rossi AM, et al. Radiolabelled nanohydroxyapatite with 99mTc: perspectives to nanoradiopharmaceuticals construction. Artif Cells Nanomed Biotechnol. 2014; 42(2): 88–91.
  6. Islamian JP, Hatamian M, Rashidi MR. Nanoparticles promise new methods to boost oncology outcomes in breast cancer. Asian Pac J Cancer Prev. 2015; 16(5): 1683–1686.
  7. Jiang X, Xin H, Ren Q, et al. Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials. 2014; 35(1): 518–529.
  8. Brannon-Peppas L, Blanchette J. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2012; 64: 206–212.
  9. Yezhelyev MV, Gao X, Xing Y, et al. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2006; 7(8): 657–667.
  10. Okarvi SM, Al Jammaz I. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors. Nucl Med Biol. 2010; 37(3): 277–288.
  11. Aghaee F, Pirayesh Islamian J, Baradaran B. Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy. J Breast Cancer. 2012; 15(2): 141–147.
  12. Gupta S, Farooque A, Adhikari JS, et al. Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors. J Cancer Res Ther. 2009; 5 Suppl 1: S16–S20.
  13. Ahmad I, Mustafa E, Mustafa N, et al. 2DG enhances the susceptibility of breast cancer cells to doxorubicin. Open Life Sciences. 2010; 5(6).
  14. Willmann JK, van Bruggen N, Dinkelborg LM, et al. Molecular imaging in drug development. Nat Rev Drug Discov. 2008; 7(7): 591–607.
  15. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov. 2003; 2(2): 123–131.
  16. Weissleder R. Molecular imaging in cancer. Science. 2006; 312(5777): 1168–1171.
  17. Gomes CM, Abrunhosa AJ, Ramos P, et al. Molecular imaging with SPECT as a tool for drug development. Adv Drug Deliv Rev. 2011; 63(7): 547–554.
  18. Ferro-Flores G, Ocampo-García B, Santos-Cuevas C, et al. Multifunctional Radiolabeled Nanoparticles for Targeted Therapy. Curr Med Chem. 2013; 21(1): 124–138.
  19. Müller C, Schibli R. Single hoton emission comuted tomograhy tracer. Molecular Imaging in Oncology: Sringer; 2013. p. : 65–105.
  20. Pirayesh Islamian J, Hatamian M, Aval NA, et al. Targeted superparamagnetic nanoparticles coated with 2-deoxy-d-gloucose and doxorubicin more sensitize breast cancer cells to ionizing radiation. Breast. 2017; 33: 97–103.
  21. Chen Y, Huang ZW, He L, et al. Synthesis and evaluation of a technetium-99m-labeled diethylenetriaminepentaacetate-deoxyglucose complex ([99mTc]-DTPA-DG) as a potential imaging modality for tumors. Appl Radiat Isot. 2006; 64(3): 342–347.
  22. Andringa KK, Coleman MC, Aykin-Burns N, et al. Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-D-glucose. Cancer Res. 2006; 66(3): 1605–1610.
  23. Ozgur A, Lambrecht FY, Ocakoglu K, et al. Synthesis and biological evaluation of radiolabeled photosensitizer linked bovine serum albumin nanoparticles as a tumor imaging agent. Int J Pharm. 2012; 422(1-2): 472–478.
  24. Dória ML, Cotrim Z, Macedo B, et al. Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells. Breast Cancer Res Treat. 2012; 133(2): 635–648.
  25. Liang Z, Li X, Xie Y, et al. 'Smart' gold nanoshells for combined cancer chemotherapy and hyperthermia. Biomed Mater. 2014; 9(2): 025012.
  26. Wang Y, Zhu J, Song X, et al. Synthesis and evaluation of (99m)Tc-2-[(3-carboxy-1-oxopropyl)amino]-2-deoxy-D-glucose as a potential tumor imaging agent. Bioorg Med Chem Lett. 2014; 24(16): 3882–3885.
  27. Polyak A, Palade EA, Balogh L, et al. In vitro and biodistribution examinations of Tc-99m-labelled doxorubicin-loaded nanoparticles. Nucl Med Rev Cent East Eur. 2011; 14(2): 55–62.
  28. Morales-Avila E, Ocampo-García BE, et al. de María Ramírez F, Radiolabeled nanoparticles for molecular imaging: Citeseer. ; 2012.
  29. Assadi M, Afrasiabi K, Nabipour I, et al. Nanotechnology and nuclear medicine; research and preclinical applications. Hell J Nucl Med. 2011; 14(2): 149–159.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl